209 related articles for article (PubMed ID: 35427376)
1. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Fu S; Bhattacharyya SK; El-Arabi AM; Cutone BJ; McVary KT
PLoS One; 2022; 17(4):e0266824. PubMed ID: 35427376
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore.
Chay J; Tung JYM; Su RJ; Aslim EJ; Wong C; Swan G; Chua WJ; Ho HSS; Finkelstein EA
J Med Econ; 2023; 26(1):1269-1277. PubMed ID: 37800562
[TBL] [Abstract][Full Text] [Related]
3. Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.
Franco JV; Jung JH; Imamura M; Borofsky M; Omar MI; Escobar Liquitay CM; Young S; Golzarian J; Veroniki AA; Garegnani L; Dahm P
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013656. PubMed ID: 34693990
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):113-118. PubMed ID: 35689083
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia.
Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Amorosi SL; Shore ND
J Health Econ Outcomes Res; 2021 May; 8(1):42-50. PubMed ID: 33987450
[No Abstract] [Full Text] [Related]
6. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.
Cornu JN; Zantek P; Burtt G; Martin C; Martin A; Springate C; Chughtai B
Eur Urol; 2023 Jun; 83(6):534-547. PubMed ID: 36964042
[TBL] [Abstract][Full Text] [Related]
7. Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis.
Franco JVA; Jung JH; Imamura M; Borofsky M; Omar MI; Escobar Liquitay CM; Young S; Golzarian J; Veroniki AA; Garegnani L; Dahm P
BJU Int; 2022 Aug; 130(2):142-156. PubMed ID: 34820997
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
Erman A; Masucci L; Krahn MD; Elterman DS
BJU Int; 2018 Nov; 122(5):879-888. PubMed ID: 30113127
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia.
Wymer KM; Narang G; Slade A; Sharma V; Thao V; Borah BJ; Rivera M; Cheney S; Humphreys MR
Urology; 2023 Jan; 171():96-102. PubMed ID: 36270339
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia A Canadian healthcare payer perspective.
Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
Can Urol Assoc J; 2023 Apr; 17(4):103-110. PubMed ID: 36486181
[TBL] [Abstract][Full Text] [Related]
11. Prostatic Artery Embolization for Benign Prostatic Hyperplasia: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(6):1-139. PubMed ID: 34188733
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan's public healthcare system.
Anezaki H; Endo F; Swan G; Takashima K; Rojanasarot S
J Med Econ; 2024; 27(1):554-565. PubMed ID: 38466193
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system.
De la Cuadra-Grande A; Rioja-Zuazu J; Domínguez-Esteban M; Torres E; Blissett R; Woodward E; Oyagüez I; Fernández-Arjona M
Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):499-510. PubMed ID: 36897833
[TBL] [Abstract][Full Text] [Related]
14. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Jung JH; McCutcheon KA; Borofsky M; Young S; Golzarian J; Reddy B; Shin TY; Kim MH; Narayan V; Dahm P
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012867. PubMed ID: 33368143
[TBL] [Abstract][Full Text] [Related]
15. Medium-Term Real-World Outcomes of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: Water Vapor Thermal Therapy (Rezum)
Chin CP; Garden EB; Ravivarapu KT; Shukla D; Omidele O; Levy M; Qian D; Araya JS; Valenzuela R; Reddy A; Marshall S; Motola J; Nobert C; Gupta M; Small AC; Kaplan SA; Palese MA
J Endourol; 2022 Dec; 36(12):1559-1566. PubMed ID: 36039926
[No Abstract] [Full Text] [Related]
16. Photovaporization of the prostate with GreenLight™ laser 180 W XPS versus transurethral resection of the prostate with monopolar energy for the treatment of benign prostatic enlargement: a cost-utility analysis from a healthcare perspective.
Caicedo JI; Taborda A; Robledo D; Bravo-Balado A; Domínguez C; Trujillo CG; Cataño JG; Campos Hernández J; Londoño Trujillo D; Plata M
World J Urol; 2019 May; 37(5):861-866. PubMed ID: 30116964
[TBL] [Abstract][Full Text] [Related]
17. Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.
Wu X; Zhou A; Heller M; Kohlbrenner R
J Vasc Interv Radiol; 2022 Dec; 33(12):1605-1615. PubMed ID: 35964881
[TBL] [Abstract][Full Text] [Related]
18. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Surgical Reintervention for Benign Prostatic Hyperplasia Following Prostatic Urethral Lift, Transurethral Resection of the Prostate, and Photoselective Vaporization of the Prostate: A TriNetX Analysis.
Feiertag JH; Kane JA; Clark JY
Eur Urol Open Sci; 2024 Jan; 59():63-70. PubMed ID: 38298771
[TBL] [Abstract][Full Text] [Related]
20. 980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study.
Cetinkaya M; Onem K; Rifaioglu MM; Yalcin V
Urol J; 2015 Nov; 12(5):2355-61. PubMed ID: 26571321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
